Discontinued — last reported Q3 '24
Accrued Compensation
Current LiabilitiesEli Lilly Accrued Compensation increased by 20.8% to $2.38B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 13.4%, from $2.09B to $2.38B. Over 5 years (FY 2020 to FY 2025), Accrued Compensation shows an upward trend with a 19.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryOther
SignalContext dependent
VolatilityModerate
First reportedQ4 2022
Last reportedQ3 2024
How to read this metric
Significant fluctuations often correlate with seasonal bonus payouts or changes in headcount and compensation structures.
Detailed definition
The liability for earned but unpaid employee wages, bonuses, commissions, and benefits at the end of the reporting perio...
Peer comparison
Standard across all industries, though sensitive to the specific compensation structure of the company.
Metric ID:
accrued_compensationHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $755.50M | $836.60M | $958.10M | $693.10M | $835.80M | $984.10M | $1.06B | $739.70M | $867.70M | $1.23B | $1.65B | $844.20M | $1.17B | $1.70B | $2.09B | $1.11B | $1.30B | $1.97B | $2.38B |
| QoQ Change | — | +10.7% | +14.5% | -27.7% | +20.6% | +17.7% | +7.7% | -30.2% | +17.3% | +42.1% | +33.8% | -48.8% | +38.4% | +45.8% | +22.9% | -46.8% | +17.0% | +50.9% | +20.8% |
| YoY Change | — | — | — | — | +10.6% | +17.6% | +10.6% | +6.7% | +3.8% | +25.3% | +55.7% | +14.1% | +34.6% | +38.1% | +26.9% | +31.9% | +11.5% | +15.4% | +13.4% |
Range$693.10M – $2.38B
CAGR+29.0%
Avg YoY Growth+21.1%
Median YoY Growth+15.4%
Current Streak3 quarters growth
Accrued Compensation at Other Companies
Frequently Asked Questions
- What is Eli Lilly's accrued compensation?
- Eli Lilly (LLY) reported accrued compensation of $2.38B in Q4 2025.
- How has Eli Lilly's accrued compensation changed year-over-year?
- Eli Lilly's accrued compensation increased by 13.4% year-over-year, from $2.09B to $2.38B.
- What is the long-term trend for Eli Lilly's accrued compensation?
- Over 5 years (2020 to 2025), Eli Lilly's accrued compensation has grown at a 19.0% compound annual growth rate (CAGR), from $997.20M to $2.38B.
- What does accrued compensation mean?
- Unpaid wages and benefits owed to employees for work already performed.